FirstWord

The Drug Development Accelerator Fund will help Formation acquire 10 to 15 drug programmes over the next three to five years.

The findings could help refine patient selection and shape the design of future stroke trials.

Rytelo, competes with Bristol Myers Squibb's Reblozyl, is already approved to treat transfusion-dependent anaemia in patients with lower-risk myelodysplastic syndromes.

One-man company Mithril developed a proof-of-principle for a bispecific antibody treatment for a rare muscular dystrophy in less than 18 months by using Claude to manage operations.

Seven of eight products in the pharma's growth portfolio grew by double digits, including Spinraza and Leqembi, as well as Apellis medicines Syfovre and Empaveli.

FirstWord spoke with MassGen's Ashwin Ananthakrishnan about Phase II data for Gilead's emvistegrast to treat ulcerative colitis, and how the oral α4β7 integrin inhibitor could affect practice patterns in IBD.

GSK is talking up its broader pipeline, but analysts couldn't get past concerns over the likelihood of success for upcoming readouts from its long-acting HIV therapies.

FirstWord previews a particularly busy month of PDUFA dates, with at least 13 decisions on the docket.

The PLATINUM-Truveta retrospective cohort analysis compared the effectiveness of semaglutide 2.4 mg and resmetirom on liver enzymes and cardiometabolic markers in people with MASHNew post hoc data fro...

ALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individualsThe Company believes implementation...